More insulin increases glucose in the muscle and fat cells, availing more energy
Inhibition of fat production AOD 9604 inhibits adipogenesis through the following mechanisms: Inhibition of adipocyte differentiation: AOD 9604 can down-regulate the expression of peroxisome proliferator-activated receptor (PPAR) and CCAAT/ enhancer binding protein (C/EBP), and block the differentiation of preadipocytes into mature adipocytes
No admission is necessarily intended, nor should it be construed, that any of the preceding information constitutes prior art against the present invention
In further embodiments, the invention encompasses a method of treating obesity or related chronic metabolic condition by administering a therapeutically effective amount of one or more cations chosen from 1c, 1f, 1l, 1m, 2j, 2k, 2l, 2m, 2aa, 1c, 1f, 1l, 1m, 2j, 2k, 2l, 2m, and 2aa
Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials
